Aspreva Pharma (ASPV) Reports Q3 EPS of $0.65
More News related to ASPV
- Aspreva Pharma (ASPV) Reports Q3 EPS of $0.65
- Raymond James downgrades Aspreva Pharmaceuticals (ASPV) to Market Perform
- StreetInsider.com Unusual 11 Mid-Day Movers 10/18
- StreetInsider.com Notable Mergers and Acquisitions of the Day 10/18
- StreetInsider.com Pre-Open Movers 10/18
More News related to Earnings
- Sprint Nextel (S) Completes Tender Offer for iPCS, Inc. (IPCS)
- Ford (F) and Geely Reportedly Clear Hurdle On Possible Volvo Deal
- Starent Networks (STAR) To Settle Shareholder Class Action Suit In Connection With Proposed Merger with Cisco (CSCO)
- Hurray! Holding (HRAY) To Acquire Ku6 in All Stock Transaction
Aspreva Pharma (Nasdaq: ASPV) reported Q3 EPS of $0.65, which may not compare to the consensus of $1.08. Revenues were $62.3 million, versus the consensus of $62.17 million.
Aspreva Pharmaceuticals Corp. is a pharmaceutical company focused on identifying, developing and commercializing existing approved drugs and drug candidates for new indications.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
